Darren S Cline Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Darren S Cline.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Darren S Cline. Darren S Cline is EVP, Commercial in SEATTLE GENETICS INC /WA ($SGEN) and Executive Vice President in SEATTLE GENETICS INC /WA ($SGEN) and See Remarks in SEATTLE GENETICS INC /WA ($SGEN) and SVP, Commercial in SEATTLE GENETICS INC /WA ($SGEN) and Director in STEMLINE THERAPEUTICS INC ($STML) and U.S. Chief Commercial Officer in GW PHARMACEUTICALS PLC ($GWPH).
Latest Insider Trading Transactions of Darren S Cline
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, GWPH, SGEN, STML
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 75,024 | 128 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 46,896 | 80 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 177,180 | 301 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 106,320 | 181 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 98,040 | 167 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 0.00 | 22,068 | 38 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | D | 15.30 | 54,192 | 829,230 | 0 | |
| May 07 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Sell | D | 0.00 | 5,556 | 0 | 0 | 5.6 K to 0 (-100.00 %) |
| Mar 04 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 46,896 | 66 | 46,896 | |
| Mar 04 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 75,024 | 105 | 75,024 | |
| Feb 24 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 75,024 | 105 | 75,024 | |
| Feb 24 2021 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 46,896 | 66 | 46,896 | |
| Jun 10 2020 | STML | STEMLINE THERAPEUT ... | Cline Darren S | Director | Sell | U | 0.00 | 35,468 | 0 | 0 | 35.5 K to 0 (-100.00 %) |
| Jun 08 2020 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 106,320 | 138 | 106,320 | |
| Jun 08 2020 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 177,180 | 230 | 177,180 | |
| May 29 2020 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | M | 0.00 | 7,356 | 9 | 0 | |
| May 29 2020 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Payment of Exercise | F | 10.54 | 1,800 | 18,972 | 5,556 | 3.8 K to 5.6 K (+47.92 %) |
| May 29 2020 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Buy | M | 0.00 | 7,356 | 9 | 7,356 | 0 to 7.4 K |
| Jun 28 2019 | STML | STEMLINE THERAPEUT ... | Cline Darren S | Director | Grant | A | 0.00 | 15,000 | 0 | 35,468 | 20.5 K to 35.5 K (+73.29 %) |
| May 30 2019 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 0.00 | 98,040 | 127 | 98,040 | |
| May 30 2019 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Option Exercise | A | 15.30 | 54,192 | 829,138 | 54,192 | |
| May 30 2019 | GWPH | GW PHARMACEUTICALS ... | Cline Darren S | U.S. Chief Commerci ... | Grant | A | 0.00 | 29,424 | 38 | 29,424 | 0 to 29.4 K |
| Nov 30 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 62.88 | 7,000 | 440,160 | 72,556 | 79.6 K to 72.6 K (-8.80 %) |
| Nov 21 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 56.68 | 4,167 | 236,204 | 79,556 | 83.7 K to 79.6 K (-4.98 %) |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 76.86 | 42,984 | 3,303,750 | 42,984 | |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 76.86 | 1,301 | 99,995 | 1,301 | |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Grant | A | 0.00 | 18,644 | 0 | 83,723 | 65.1 K to 83.7 K (+28.65 %) |
| Aug 29 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 74.23 | 4,784 | 355,125 | 65,079 | 69.9 K to 65.1 K (-6.85 %) |
| Aug 29 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 74.23 | 4,784 | 355,125 | 65,079 | 69.9 K to 65.1 K (-6.85 %) |
| Jun 22 2018 | STML | STEMLINE THERAPEUT ... | Cline Darren S | Director | Grant | A | 0.00 | 20,468 | 0 | 20,468 | 0 to 20.5 K |
| Jun 22 2018 | STML | STEMLINE THERAPEUT ... | Cline Darren S | Director | Grant | A | 0.00 | 20,468 | 0 | 20,468 | 0 to 20.5 K |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 31.37 | 8,000 | 250,960 | 1,583 | |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 26.10 | 926 | 24,169 | 0 | |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 16.41 | 892 | 14,638 | 0 | |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 15.46 | 268 | 4,143 | 0 | |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 69.03 | 1,250 | 86,284 | 69,863 | 71.1 K to 69.9 K (-1.76 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 68.90 | 718 | 49,470 | 71,113 | 71.8 K to 71.1 K (-1.00 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 69.00 | 8,000 | 552,000 | 71,831 | 79.8 K to 71.8 K (-10.02 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 31.37 | 8,000 | 250,960 | 79,831 | 71.8 K to 79.8 K (+11.14 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 69.00 | 926 | 63,894 | 71,831 | 72.8 K to 71.8 K (-1.27 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 26.10 | 926 | 24,169 | 72,757 | 71.8 K to 72.8 K (+1.29 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 69.00 | 268 | 18,492 | 71,831 | 72.1 K to 71.8 K (-0.37 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 15.46 | 268 | 4,143 | 72,099 | 71.8 K to 72.1 K (+0.37 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 69.00 | 892 | 61,548 | 71,831 | 72.7 K to 71.8 K (-1.23 %) |
| Jun 14 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 16.41 | 892 | 14,638 | 72,723 | 71.8 K to 72.7 K (+1.24 %) |
| May 11 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 16.41 | 7,000 | 114,870 | 892 | |
| May 11 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 15.46 | 2,000 | 30,920 | 268 | |
| May 11 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 55.33 | 9,000 | 497,983 | 71,831 | 80.8 K to 71.8 K (-11.13 %) |
| May 11 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 15.46 | 2,000 | 30,920 | 80,831 | 78.8 K to 80.8 K (+2.54 %) |
| May 11 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 16.41 | 7,000 | 114,870 | 78,831 | 71.8 K to 78.8 K (+9.75 %) |
| May 07 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 53.81 | 4,000 | 215,238 | 71,831 | 75.8 K to 71.8 K (-5.27 %) |
| Mar 22 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | See Remarks | Option Exercise | A | 34.20 | 8,333 | 284,989 | 8,333 | |
| Feb 07 2018 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | D | 55.58 | 1,399 | 77,756 | 75,831 | 77.2 K to 75.8 K (-1.81 %) |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 15.46 | 5,024 | 77,671 | 2,268 | |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 16.41 | 5,024 | 82,444 | 0 | |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 51.94 | 5,024 | 260,967 | 77,230 | 82.3 K to 77.2 K (-6.11 %) |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 15.46 | 5,024 | 77,671 | 82,254 | 77.2 K to 82.3 K (+6.51 %) |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 16.41 | 5,024 | 82,444 | 77,230 | 72.2 K to 77.2 K (+6.96 %) |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 18.46 | 2,907 | 53,663 | 0 | |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 52.51 | 4,662 | 244,794 | 72,206 | 76.9 K to 72.2 K (-6.06 %) |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 52.52 | 2,907 | 152,672 | 76,868 | 79.8 K to 76.9 K (-3.64 %) |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 18.46 | 2,907 | 53,663 | 79,775 | 76.9 K to 79.8 K (+3.78 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 47.89 | 1,788 | 85,635 | 76,868 | 78.7 K to 76.9 K (-2.27 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 46.37 | 40,344 | 1,870,751 | 40,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Grant | A | 0.00 | 17,000 | 0 | 78,656 | 61.7 K to 78.7 K (+27.57 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 18.46 | 6,000 | 110,760 | 2,907 | |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 49.19 | 6,000 | 295,110 | 61,656 | 67.7 K to 61.7 K (-8.87 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 18.46 | 6,000 | 110,760 | 67,656 | 61.7 K to 67.7 K (+9.73 %) |
| Dec 20 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 16.41 | 3,100 | 50,871 | 5,024 | |
| Dec 20 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 16.41 | 3,100 | 50,871 | 61,604 | 58.5 K to 61.6 K (+5.30 %) |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 26.10 | 10,000 | 261,000 | 926 | |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 18.46 | 2,761 | 50,968 | 0 | |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 64.35 | 1,194 | 76,833 | 58,504 | 59.7 K to 58.5 K (-2.00 %) |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 18.46 | 2,761 | 50,968 | 59,698 | 56.9 K to 59.7 K (+4.85 %) |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 63.25 | 8,806 | 557,002 | 56,937 | 65.7 K to 56.9 K (-13.39 %) |
| Dec 15 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 26.10 | 10,000 | 261,000 | 65,743 | 55.7 K to 65.7 K (+17.94 %) |
| Sep 13 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 15.46 | 4,167 | 64,422 | 0 | |
| Sep 13 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 15.46 | 4,167 | 64,422 | 55,743 | 51.6 K to 55.7 K (+8.08 %) |
| Sep 08 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 46.02 | 771 | 35,479 | 51,576 | 52.3 K to 51.6 K (-1.47 %) |
| Sep 08 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 46.01 | 4,626 | 212,828 | 52,347 | 57 K to 52.3 K (-8.12 %) |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 45.30 | 37,793 | 1,712,023 | 37,793 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 45.30 | 2,207 | 99,977 | 2,207 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Grant | A | 0.00 | 16,000 | 0 | 56,973 | 41 K to 57 K (+39.05 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 46.59 | 1,774 | 82,652 | 40,973 | 42.7 K to 41 K (-4.15 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Option Exercise | A | 39.15 | 27,780 | 1,087,587 | 27,780 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Option Exercise | A | 39.15 | 2,220 | 86,913 | 2,220 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Grant | A | 0.00 | 12,000 | 0 | 43,482 | 31.5 K to 43.5 K (+38.12 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Sell | S | 42.02 | 2,231 | 93,757 | 31,482 | 33.7 K to 31.5 K (-6.62 %) |
| Jun 06 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 42.07 | 3,366 | 141,617 | 42,747 | 46.1 K to 42.7 K (-7.30 %) |
| Mar 03 2016 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | Executive Vice Pres ... | Grant | A | 0.00 | 8,400 | 0 | 46,113 | 37.7 K to 46.1 K (+22.27 %) |
| Nov 13 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Sell | S | 45.68 | 5,769 | 263,548 | 37,713 | 43.5 K to 37.7 K (-13.27 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Option Exercise | A | 39.15 | 27,780 | 1,087,587 | 27,780 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Option Exercise | A | 39.15 | 2,220 | 86,913 | 2,220 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Grant | A | 0.00 | 12,000 | 0 | 43,482 | 31.5 K to 43.5 K (+38.12 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Sell | S | 42.02 | 2,231 | 93,757 | 31,482 | 33.7 K to 31.5 K (-6.62 %) |
| Mar 17 2015 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | SVP, Commercial | Sell | S | 38.65 | 7,500 | 289,876 | 33,135 | 40.6 K to 33.1 K (-18.46 %) |
Page: 1